C3300201: A Phase 2 Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate the Efficacy, Safety, and Tolerability of 2 Dose Levels of IW3300 Administered Rectally for 12 Weeks to Treat Bladder Pain in Subjects with Interstitial Cystitis/Bladder Pain Syndrome
Study of IW-3300 in Patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Sponsor: Ironwood Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU6981
U.S. Govt. ID: NCT05740007
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if IW-3300, an investigational new drug, helps bladder pain when given as a rectal (inserted into the anus) foam. The study will test IW-3300. IW-3300 is a new drug that has been developed for treating people like you with interstitial cystitis/bladder pain syndrome. It is not yet approved by the United States Food and Drug Administration (FDA). It can only be used in a study like this one.
This study is closed
Investigator
Svjetlana Lozo, MD, MPH
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with IC/BPS? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Reena Vattakalam
rmv2110@cumc.columbia.edu
212-342-6895